Correction to October 2015 issue

In last month's issue, the article “Empagliflozin associated with reduced mortality risk in patients with cardiovascular disease” contained errors.

In fact, 490 of 4,687 patients (10.5%) in the empagliflozin group and 282 of 2,333 placebo patients (12.1%) met the study's primary outcome, a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, rather than death as was reported. Also, hospitalization for unstable angina occurred in 133 empagliflozin patients (2.8%) and 66 placebo patients (2.8%), for a hazard ratio (HR) of 0.99. The key secondary outcome, a composite of the primary outcome plus hospitalization for unstable angina, occurred in 599 of 4,687 patients (12.8%) in the empagliflozin group and 333 of 2,333 patients (14.3%) in the placebo group (HR, 0.89; 95% CI, 0.78 to 1.01; P<0.001 for noninferiority and P=0.08 for superiority). The original article has been corrected.